vs

Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

USCB FINANCIAL HOLDINGS, INC. is the larger business by last-quarter revenue ($22.2M vs $20.0M, roughly 1.1× AGIOS PHARMACEUTICALS, INC.). USCB FINANCIAL HOLDINGS, INC. runs the higher net margin — 6.1% vs -541.1%, a 547.2% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 14.7%). USCB FINANCIAL HOLDINGS, INC. produced more free cash flow last quarter ($42.5M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 12.3%).

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

AGIO vs USCB — Head-to-Head

Bigger by revenue
USCB
USCB
1.1× larger
USCB
$22.2M
$20.0M
AGIO
Growing faster (revenue YoY)
AGIO
AGIO
+71.4% gap
AGIO
86.1%
14.7%
USCB
Higher net margin
USCB
USCB
547.2% more per $
USCB
6.1%
-541.1%
AGIO
More free cash flow
USCB
USCB
$139.8M more FCF
USCB
$42.5M
$-97.3M
AGIO
Faster 2-yr revenue CAGR
AGIO
AGIO
Annualised
AGIO
56.1%
12.3%
USCB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGIO
AGIO
USCB
USCB
Revenue
$20.0M
$22.2M
Net Profit
$-108.0M
$1.4M
Gross Margin
90.6%
Operating Margin
-608.9%
14.7%
Net Margin
-541.1%
6.1%
Revenue YoY
86.1%
14.7%
Net Profit YoY
-11.9%
-80.3%
EPS (diluted)
$-1.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGIO
AGIO
USCB
USCB
Q4 25
$20.0M
$22.2M
Q3 25
$12.9M
$25.0M
Q2 25
$12.5M
$24.4M
Q1 25
$8.7M
$22.8M
Q4 24
$10.7M
$23.0M
Q3 24
$9.0M
$21.5M
Q2 24
$8.6M
$20.5M
Q1 24
$8.2M
$17.6M
Net Profit
AGIO
AGIO
USCB
USCB
Q4 25
$-108.0M
$1.4M
Q3 25
$-103.4M
$8.9M
Q2 25
$-112.0M
$8.1M
Q1 25
$-89.3M
$7.7M
Q4 24
$-96.5M
$6.9M
Q3 24
$947.9M
$6.9M
Q2 24
$-96.1M
$6.2M
Q1 24
$-81.5M
$4.6M
Gross Margin
AGIO
AGIO
USCB
USCB
Q4 25
90.6%
Q3 25
87.0%
Q2 25
86.3%
Q1 25
87.6%
Q4 24
88.3%
Q3 24
91.3%
Q2 24
82.6%
Q1 24
92.3%
Operating Margin
AGIO
AGIO
USCB
USCB
Q4 25
-608.9%
14.7%
Q3 25
-907.4%
47.3%
Q2 25
-1020.1%
44.0%
Q1 25
-1222.0%
44.2%
Q4 24
-1165.3%
39.6%
Q3 24
-1146.9%
42.5%
Q2 24
-1228.3%
39.8%
Q1 24
-1124.3%
34.3%
Net Margin
AGIO
AGIO
USCB
USCB
Q4 25
-541.1%
6.1%
Q3 25
-803.1%
35.8%
Q2 25
-899.4%
33.4%
Q1 25
-1023.3%
33.5%
Q4 24
-899.6%
30.0%
Q3 24
10574.7%
32.3%
Q2 24
-1115.7%
30.3%
Q1 24
-995.8%
26.2%
EPS (diluted)
AGIO
AGIO
USCB
USCB
Q4 25
$-1.86
Q3 25
$-1.78
$0.45
Q2 25
$-1.93
Q1 25
$-1.55
Q4 24
$-1.44
Q3 24
$16.22
$0.35
Q2 24
$-1.69
Q1 24
$-1.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGIO
AGIO
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$89.1M
$38.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
$217.2M
Total Assets
$1.3B
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGIO
AGIO
USCB
USCB
Q4 25
$89.1M
$38.5M
Q3 25
$92.7M
$56.8M
Q2 25
$80.9M
$54.8M
Q1 25
$79.0M
$98.0M
Q4 24
$76.2M
$77.0M
Q3 24
$253.7M
$38.5M
Q2 24
$84.5M
$77.3M
Q1 24
$118.8M
$126.5M
Stockholders' Equity
AGIO
AGIO
USCB
USCB
Q4 25
$1.2B
$217.2M
Q3 25
$1.3B
$209.1M
Q2 25
$1.4B
$231.6M
Q1 25
$1.5B
$225.1M
Q4 24
$1.5B
$215.4M
Q3 24
$1.6B
$213.9M
Q2 24
$660.5M
$201.0M
Q1 24
$743.9M
$195.0M
Total Assets
AGIO
AGIO
USCB
USCB
Q4 25
$1.3B
$2.8B
Q3 25
$1.4B
$2.8B
Q2 25
$1.5B
$2.7B
Q1 25
$1.6B
$2.7B
Q4 24
$1.7B
$2.6B
Q3 24
$1.8B
$2.5B
Q2 24
$773.1M
$2.5B
Q1 24
$849.7M
$2.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGIO
AGIO
USCB
USCB
Operating Cash FlowLast quarter
$-96.2M
$42.8M
Free Cash FlowOCF − Capex
$-97.3M
$42.5M
FCF MarginFCF / Revenue
-487.5%
191.4%
Capex IntensityCapex / Revenue
5.6%
1.4%
Cash ConversionOCF / Net Profit
31.40×
TTM Free Cash FlowTrailing 4 quarters
$-377.3M
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGIO
AGIO
USCB
USCB
Q4 25
$-96.2M
$42.8M
Q3 25
$-88.2M
$20.1M
Q2 25
$-77.1M
$18.0M
Q1 25
$-111.5M
$14.6M
Q4 24
$-133.2M
$34.8M
Q3 24
$-84.2M
$11.3M
Q2 24
$-72.6M
$18.3M
Q1 24
$-99.9M
$8.1M
Free Cash Flow
AGIO
AGIO
USCB
USCB
Q4 25
$-97.3M
$42.5M
Q3 25
$-89.7M
$20.0M
Q2 25
$-78.0M
$18.0M
Q1 25
$-112.3M
$14.6M
Q4 24
$-134.1M
$34.5M
Q3 24
$-84.6M
$11.2M
Q2 24
$-72.7M
$18.2M
Q1 24
$-100.0M
$8.0M
FCF Margin
AGIO
AGIO
USCB
USCB
Q4 25
-487.5%
191.4%
Q3 25
-696.5%
80.3%
Q2 25
-626.2%
73.7%
Q1 25
-1286.4%
63.9%
Q4 24
-1250.1%
150.2%
Q3 24
-944.2%
52.2%
Q2 24
-844.4%
88.8%
Q1 24
-1221.2%
45.4%
Capex Intensity
AGIO
AGIO
USCB
USCB
Q4 25
5.6%
1.4%
Q3 25
12.1%
0.5%
Q2 25
7.0%
0.2%
Q1 25
8.8%
0.2%
Q4 24
9.0%
1.4%
Q3 24
4.7%
0.4%
Q2 24
1.8%
0.4%
Q1 24
1.7%
0.5%
Cash Conversion
AGIO
AGIO
USCB
USCB
Q4 25
31.40×
Q3 25
2.25×
Q2 25
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
-0.09×
1.63×
Q2 24
2.95×
Q1 24
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons